XENE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XENE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Xenon Pharmaceuticals's intangible assets for the quarter that ended in Mar. 2024 was $0.00 Mil.
The historical data trend for Xenon Pharmaceuticals's Intangible Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Intangible Assets | Get a 7-Day Free Trial | - | - | - | - | - |
Xenon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intangible Assets | Get a 7-Day Free Trial | - | - | - | - | - |
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.
Xenon Pharmaceuticals (NAS:XENE) Intangible Assets Explanation
If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.
The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.
Some intangibles are amortized. Amortization is the depreciation of intangible assets.
Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.
Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.
If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.
Intangibles acquired are on balance sheet at fair value.
Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.
One of the reasons competitive advantage power can remain hidden for so long.
Be Aware
Companies may change the way intangible assets are amortized, and this will affect their reported earnings.
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary Patou | director | |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Justin D. Gover | director | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Steven Gannon | director | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8 |
Simon N. Pimstone | director | 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Ian Mortimer | director, officer: PRESIDENT & CEO | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Christopher John Kenney | officer: Chief Medical Officer | 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W |
Andrea Difabio | officer: Chief Legal Officer | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Sherry Aulin | officer: Chief Financial Officer | 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W |
Sherrington Robin | officer: SVP Bus. & Corp. Development | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
James R. Empfield | officer: SVP, Drug Discovery | 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W |
Seggern Christopher Von | officer: Chief Commercial Officer | 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W |
From GuruFocus
By sperokesalga sperokesalga • 02-08-2023
By Marketwired • 08-08-2023
By Value_Insider Value_Insider • 12-02-2022
By Stock market mentor Stock market mentor • 01-09-2023
By GuruFocus Research • 05-27-2023
By sperokesalga sperokesalga • 04-18-2023
By Marketwired • 09-12-2023
By Value_Insider Value_Insider • 11-09-2022
By Marketwired • 08-02-2023
By sperokesalga sperokesalga • 05-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.